- Oops!Something went wrong.Please try again later.
76.88% of the Company’s share capital was represented at the AGM and resolutions were all widely approved
GENEVA, Switzerland, June 02, 2022--(BUSINESS WIRE)--Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 31, 2022. These included among others:
Approval of the annual report and accounts for the year ended 31 December 2021
Re-election/election of the Chairman and all Members of the Board of Directors
Approval of maximum aggregate Board of Directors and Managerial compensation for 2023
Re-election of PricewaterhouseCoopers, Geneva, as auditors
Approval of new authorized capital and new conditional capital
76.88% of the Company’s share capital was represented at the AGM and resolutions were all widely approved. Detailed results are available on the Company’s website at: http://www.geneuro.com/en/investors/general-meetings.
Forthcoming investor and industry events:
June 13-16, 2022: BIO International Convention, San Diego, USA
June 28, 2022: Gilbert Dupont Small & Midcaps Forum, Paris, France
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601006101/en/
Chairman and CEO
+41 22 552 48 00
Louis-Victor Delouvrier /
Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 00 15